Gain Therapeutics (GANX) Status Update summary

Management and leadership update

• Interim CEO and CFO roles assumed by Gene Mack following the departure of Matthias Alder.

• Dr. Khalid Islam, founder and chairman, appointed as executive chairman to support management and clinical strategy.

• No changes to business strategy or objectives following management transition.

Financial and operational highlights

• Raised $11 million in a public offering, netting approximately $10 million after fees.

• Proceeds will fund clinical and non-clinical development of GT-02287 and general corporate purposes.

• Financing enables initiation of a Phase 1b proof-of-concept study in Parkinson's disease patients.

Clinical development and trial updates

• GT-02287 is in Phase I clinical development for Parkinson's disease.

• Single ascending dose Phase I trial showed GT-02287 was well tolerated with no serious adverse events.

• Multiple ascending dose Phase I trial expected to complete all four cohorts by mid-2024, with top-line data in August and full results at a major conference in September.